MedTrace Logo

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT03233438 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2020-01-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin Structure Infections)

Conditions

Interventions

DRUG

Dalbavancin

Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.

DRUG

Usual Care

Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Patrick Gillard · Allergan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-24
Primary Completion
2018-10-30
Completion
2018-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03233438 on ClinicalTrials.gov